Hikma Pharma shares rise on 'unsolicited enquiries'
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."
The share price rose 4.85% to 908p by 12:05.
NR